louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01332916: Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging
Official title: Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Breast Cancer
Healthy
Keywords: No metastatic breast cancer
cognitive troubles
adjuvant chemotherapy
Lead sponsor: Centre Francois Baclesse
Sponsor class: OTHER
First posted: 2011-04-11
Enrollment: 60
Sex: FEMALE
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this study is to investigate memory problems in patients with cancer.


Eligibility criteria: Inclusion Criteria for patients:

* Patients aged 45 and over
* Patients from Grade 3 'end of primary schooling "minimum (scale Barbizet)
* Non-Metastatic Breast Cancer
* Adjuvant Chemotherapy: FEC, including Docetaxel Protocols
* No major cognitive impairment
* No previous neurological
* Lack of personality disorders and psychiatric disorders evolutionary
* Having signed the informed consent of study participation

Inclusion Criteria for control group:

* Women from the general population aged 45 and over, and matched in age and cultural level in patients
* Topics of Grade 3 'end of primary schooling "minimum (scale Barbizet)
* No prior cancer
* No major cognitive impairment
* No previous neurological
* Lack of personality disorders and psychiatric disorders evolutionary
* Participating in the IMAP Protocol No. ID-BCR: 2007-A00414-49 or IMAP+(n° ID RCB 2011-A01493-38)(see how the study below) have signed forms no objection and consent to study participation

Exclusion Criteria:

Traduction (français \> anglais)

* Metastatic
* Cancer of the breast other than primitive
* Patients with paraneoplastic syndrome
* Patients under 45 years
* Patients whose achievement is below level 3 'end of primary schooling "(scale Barbizet)
* Patients with adjuvant chemotherapy is associated with targeted therapy
* Patients who have received other cancer treatments (chemotherapy or radiotherapy brain)
* Contraindication to the implementation of an MRI (claustrophobia, metal objects in the body)
* disorders of higher functions existing in the administration of chemotherapy
* Neurologic earlier
* Pathology psychiatric evolutionary
* Refusal of participation
* Patients unable to meet the cognitive tests
* Drug use
* Heavy drinking

Primary outcomes:
measure: Assess the relationship between memory impairment and brain dysfunction
timeFrame: Before chemotherapy (baseline), end of chemotherapy and follow-up up to 12 months after chemotherapy
Secondary outcomes:
measure: Impact of age
timeFrame: Before chemotherapy (baseline), end of chemotherapy and follow-up up to 12 months after chemotherapy
Other outcomes:
Locations:
city: Caen
country: France
facility: Centre de recherche CYCERON
state: Calvados
city: Caen
country: France
facility: Centre François BACLESSE
state: Calvados
Study officials:
References:
Clinical trial NCT06383416: Incidence of Headache and Its Effect on Quality of Life in Geriatric Patients With Chronic Neck Pain
Official title: Incidence of Headache and Its Effect on Quality of Life in Geriatric Patients With Chronic Neck Pain
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Geriatric Patients With Neck Pain
Lead sponsor: Ahram Canadian University
Sponsor class: OTHER
First posted: 2024-04-25
Enrollment: 40
Sex: ALL
Minimum age (years): 60
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: geriatric patients with age range from 60-70 suffering from neck pain

Brief summary: cross sectional study to detect the incidence of headache and its effect on quality of life in geriatric patients with chronic neck pain. Patients will fill out quality of life questionnaire and headache disability index. We will take information from the patients about:

* The frequency of headache occurrence.
* Visual analogue scale of chronic neck pain. Main measures: chronic neck pain will be assessed by visual analogue scale. Patients will fill out quality of life questionnaire and headache disability index.


Eligibility criteria: Inclusion Criteria:

- geriatric patient with neck pain from 1moth ago

Exclusion Criteria:

* patient with the following conditions autoimmune disease neurological disease have previous cervical surgery

Primary outcomes:
measure: Visual analogue scale
timeFrame: one time
measure: headache disability index
timeFrame: one time
measure: SF-36 quality of life questionare
timeFrame: one time
Secondary outcomes:
Other outcomes:
Locations:
city: Banī Suwayf
country: Egypt
facility: Ababa physical therapy center
Study officials:
References:
Clinical trial NCT01427816: A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome
Official title: A Randomized, Double Blind, Placebo Controlled, Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Dry Eye Syndromes
Keywords: Dry eye syndromes
Corneal diseases
Conjunctival diseases
Lead sponsor: Kissei Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2011-09-02
Enrollment: 180
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndrome.


Eligibility criteria: Inclusion Criteria:

* Corneal and conjunctival damage
* Insufficiency of lacrimal secretion
* Ocular symptom

Exclusion Criteria:

* Severe ophthalmic disorder
* Punctual plugs or surgery for occlusion of the lacrimal puncta

Primary outcomes:
measure: Corneal staining score
timeFrame: 6 weeks
Secondary outcomes:
measure: Conjunctival staining score
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Tokyo and Other Japanese City
country: Japan
facility: Japan
Study officials:
affiliation: Clinical Development Department, Kissei pharmaceutical Co., Ltd.
name: Katsumi Hontani
role: STUDY_DIRECTOR
References:
Clinical trial NCT00419016: Association Between Schizophrenia and Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Schizophrenia
Cancer
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2007-01-05
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: A family study of the negative association betweeen schizophrenia and cancer


Eligibility criteria: Inclusion Criteria:

* schizophrenia

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: The Gertner Institute
name: Gilad Gal, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05365516: Medical Safety Huddles - a Multi-site QI Project
Official title: Medical Safety Huddles - a Multi-site QI (Quality Improvement) Project
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patient Safety
Keywords: Quality Improvement
Patient Safety
Physician Engagement
Huddles
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
Collaborators: name: Sinai Health System
name: Sunnybrook Health Sciences Centre
First posted: 2022-05-09
Enrollment: 4
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: The multi-centre QI project will use a stepped wedge cluster randomized design
Primary purpose: OTHER

Brief summary: This quality improvement project will implement and evaluate the impact of physician-specific huddles, termed "medical safety huddles" on patient safety within four programs/sites at Sinai Health Systems, St. John's Rehab (Sunnybrook) and University Health Network.


Eligibility criteria: Inclusion criteria:

- Any staff physicians, residents or medical students working at the four programs/sites

Exclusion criteria:

None

Primary outcomes:
measure: Adverse events
timeFrame: 19 months
Secondary outcomes:
measure: Process measure - Attendance rate
timeFrame: 15 months
measure: Process measure - Safety issues
timeFrame: 15 months
measure: Process measure - Actions taken to address safety issues
timeFrame: 15 months
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Princess Margaret Hospital - UHN
state: Ontario1
city: Toronto
country: Canada
facility: St John's Rehab
state: Ontario
city: Toronto
country: Canada
facility: Bridgepoint Active Health
state: Ontario
city: Toronto
country: Canada
facility: Mount Sinai Hospital
state: Ontario
Study officials:
affiliation: University Health Network, Toronto
name: Meiqi Guo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02996916: Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue
Official title: Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Efficacy of Olmesartan on Cerebral Glucose Metabolism in Essential Hypertension
Lead sponsor: Kurume University
Sponsor class: OTHER
First posted: 2016-12-19
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hypertension is a leading risk factor for morbidity and mortality worldwide. The brain is a major target of the damaging effects of hypertension. Hypertension has been recognized as the leading cause of dementia as well as the most important risk factor for stroke and vascular cognitive impairment. Although glucose is the principal cerebral energy source, impact of hypertensive treatment on cerebral glucose metabolism is poorly understood.


Eligibility criteria: Inclusion Criteria:

* Written informed consent obtained
* Male and female subjects aged 20 years or older at informed consent
* Essential hypertension who had never received angiotensin II receptor antagonists and calcium channel blockers

Exclusion Criteria:

* Secondary hypertension or malignant hypertension
* Diabetes mellitus
* History or evidence of a stroke
* Hepatic or hematologic abnormality
* Mild Cognitive Impairment or Dementia
* Serum potassium level ≥ 5.5 mEq/L
* Serum creatinine level ≥ 3.0 mg/dL
* Acute or chronic disease
* Allergy to any drugs
* Pregnancy

Primary outcomes:
measure: Effects of treatment on the nominal change in cerebral glucose metabolism from baseline after 6 months of treatment as measured by FDG-PET/CT
timeFrame: 6 months of treatment
Secondary outcomes:
measure: Change from baseline in vascular inflammation measured by blood-normalized standardized uptake value, known as a target-to-background ratio (TBR) by FDG-PET/CT
timeFrame: 6 months of treatment
measure: Change from baseline in abdominal and muscle fat volume as measured by CT
timeFrame: 6 months of treatment
measure: Change from baseline in circulating inflammatory markers including hsCRP (mg/L), adiponectin (µg/mL), ADMA (nmoL/mL), DPP-4 (ng/mL), advanced glycation end products (AGEs, µg/mL) and angiotensin-(1-7) (ng/mL)
timeFrame: 6 months of treatment
Other outcomes:
Locations:
city: Kurume
country: Japan
facility: Kurume University Hospital
Study officials:
affiliation: Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine
name: Nobuhiro Tahara, MD, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06300216: A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
Official title: A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Neuroendocrine Tumors
Lead sponsor: Qilu Hospital of Shandong University
Sponsor class: OTHER
First posted: 2024-03-08
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with advanced neuroendocrine tumors treated with octreotide microspheres will be eligible to participate in the study.

Brief summary: The aim of this multicenter, open-label, observational study is to evaluate the safety and efficacy of octreotide microspheres in the treatment of advanced neuroendocrine tumors in real clinical practice, especially to evaluate the treatment of octreotide microspheres in various subgroups of neuroendocrine tumor patients.


Eligibility criteria: Inclusion Criteria:

1. Sign an informed consent form and voluntarily participate in this study;
2. Patients with unresectable or metastatic neuroendocrine tumors confirmed by histopathology. Patients with recurrence and progression after surgery or local treatment can also be included in the study;
3. Age ≥ 18 years old;
4. Treatment with octreotide microspheres.

Exclusion Criteria:

1. Confirmed pregnant or lactating women;
2. Participating in any research with intervention measures outside of routine clinical practice;
3. Other situations unsuitable for inclusion in the study determined by the researcher.

Primary outcomes:
measure: Treatment Emergent Adverse Events
timeFrame: up to 46 months
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: Qilu hospital of Shandong University
state: Shandong
Study officials:
affiliation: Qilu hospital of Shandong University, China
name: Jing Hao, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04426916: Spine Ultrasound Image Study of Spondylolisthesis Patient
Official title: Ultrasound Image Study to Evaluate the Optimal Angulation of Needle Insertion for Spinal Anesthesia in Patients With Spondylolisthesis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Spondylolisthesis
Keywords: optimal angle
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2020-06-11
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients scheduled for elective orthopedic surgery in SNUH(Seoul national university hospital) with ASA physical status classification system I, II, III.

Brief summary: This study is to evaluate the anatomical characteristics of spondylolisthesis patients using spine ultrasound imaging. The optimal angle of spinal needle insertion for spinal anesthesia in spondylolisthesis patients was compared to that of normal patients without abnormal spinal anatomy.


Eligibility criteria: Inclusion Criteria:

* Adult patients scheduled for elective orthopedic surgery.
* with ASA physical status classification system I, II, III.

Exclusion Criteria:

* Patients with communication difficulties.
* Patient who can not take a lateral decubitus position for spinal anesthesia. (e.g) fracture)
* Patients with a medical history of spinal surgery.
* Patients with significant spinal anatomical deformity any other than spondylolisthesis. (for spondylolisthesis patients group)

Primary outcomes:
measure: The predicted optimal angle of spinal needle insertion for spinal anesthesia at the level of spondylolisthesis. (alpha 1)
timeFrame: Preanesthesia
measure: The predicted optimal angle of spinal needle insertion for spinal anesthesia at the one upper level of spondylolisthesis. (alpha 2)
timeFrame: Preanesthesia
Secondary outcomes:
measure: The height of LFD measured by ultrasound image.
timeFrame: Preanesthesia
measure: The depth from skin (needle insertion point) to LFD.
timeFrame: Preanesthesia
measure: The depth from skin (needle insertion point) to posterior longitudinal ligament(PLL).
timeFrame: Preanesthesia
measure: Patients' gender, age, height, weight, BMI, etc.
timeFrame: Preanesthesia
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Jin-Tae Kim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kim Y, Yoo S, Park SK, Bae H, Lim YJ, Kim JT. Optimal angle of needle insertion for spinal anesthesia in patients with spondylolisthesis: an ultrasonographic study. BMC Anesthesiol. 2021 Sep 8;21(1):221. doi: 10.1186/s12871-021-01444-0.
Clinical trial NCT05231616: Deep Learning Model for Diagnosis and Contour of Cervical Lymph Node for Nasopharyngeal Carcinoma
Official title: Magnetic Resonance Imaging Based Deep Learning Model for Diagnosis and Contour of Cervical Lymph Node for Nasopharyngeal Carcinoma: a Multicenter Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Deep Learning Model
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2022-02-09
Enrollment: 5000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Nasopharyngeal carcinoma

Brief summary: The diagnosis of cervical lymph node in nasopharyngeal carcinoma is difficult. Magnetic resonance imaging based deep learning model may be a noninvasive and rapid diagnostic method for cervical lymph node. Thus, the investigators aimed to develop and externally validate a deep learning model to assist in the diagnosis and localization of metastatic lymph nodes in nasopharyngeal carcinoma.


Eligibility criteria: Inclusion Criteria:

* Pathological diagnosis of nasopharyngeal carcinoma; Cervival lymph nodes confirmed by pathology

Exclusion Criteria:

* a history of cancer

Primary outcomes:
measure: Sensitivity and specificity
timeFrame: 2022-12-31
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen University Cancer Center
state: Guangdong
Study officials:
References:
Clinical trial NCT01048216: Partial Liver Radiotherapy for Unresectable Liver Metastases
Official title: Partial Liver Radiotherapy for Patients With Unresectable Colorectal Liver Metastases
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Metastatic Colorectal Liver Cancer
Keywords: colorectal liver cancer
metastatic
radiation therapy
Lead sponsor: Royal Marsden NHS Foundation Trust
Sponsor class: OTHER
First posted: 2010-01-13
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: This study is designed to treat tumors in the liver that cannot be removed surgically and chemotherapy cannot control these tumors, using radiation therapy and a more precise delivery than has been used before.

Detailed description: The purpose of this study is to evaluate safety and feasibility of conformal radiation therapy in patients with metastatic colorectal liver cancer. This study would also evaluate local control rate within irradiated area and to assess failure patterns and survival of patients treated with conformal liver radiation.

Eligibility criteria: Inclusion Criteria:

* liver metastases unequivocally seen on contrast enhanced CT and/or MRI from colon or rectal cancer, previously confirmed pathologically as adenocarcinoma
* either 1) the tumor must be unresectable, 2) the patient must be medically inoperable, or 3) extra-hepatic metastases are present (making hepatic surgery an inappropriate treatment option)
* good performance status (0-1)
* Age \> 18 years. Adult patients of all ages, both sexes and all races will be included in this study. Female patients within reproductive years may not be, nor become, pregnant during participation in this study
* life expectancy \> 3 months

Exclusion Criteria:

* patients with active hepatitis or clinically significant liver failure
* patients receiving anticoagulation treatment with warfarin or heparin
* prior radiation therapy to the right upper abdomen, precluding re-irradiation of the liver
* clinically apparent ascites
* central nervous system metastases

Primary outcomes:
measure: To evaluate feasibility of conformal radiation therapy in patients with metastatic colorectal liver cancer and determine its safety
Secondary outcomes:
measure: To evaluate local control rate within irradiated fields
measure: To assess failure patterns and survival of patients treated with conformal liver radiation
measure: Set up verification with cone-beam CT (OBI on Boar Imager)
Other outcomes:
Locations:
city: Sutton
country: United Kingdom
facility: Royal Marsden NHS Foundation Trust
state: Surrey
Study officials:
affiliation: Royal Marsden NHS Foundation Trust
name: Diana Tait
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05377216: Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation
Official title: Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: EARLY_PHASE1
Conditions: Ventricular Tachycardia
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2022-05-17
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Prospective cohort study evaluating the electrophysiologic and biochemical effects of stellate ganglion block in patients with ventricular tachycardia.


Eligibility criteria: Inclusion Criteria:

* Planned catheter based VT ablation
* Age at least 18 years

Exclusion Criteria:

* Pregnancy
* Contraindication to SGB or VT ablation
* Hypersensitivity of local anesthetic of amide type
* Hemodynamic instability during the procedure prior to the study protocol

Primary outcomes:
measure: Ventricular Effective Refractory Period
timeFrame: 30 minutes following stellate ganglion block
Secondary outcomes:
measure: Ventricular Arrhythmia Inducibility
timeFrame: 30 minutes following stellate ganglion block
measure: Neuropeptide Y
timeFrame: 30 minutes following stellate ganglion block
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Hospital of the University of Pennsylvania
state: Pennsylvania
Study officials:
References: